Home| About us| login/register| For authors| For reviewers |Submit a paper
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


 Yes, sign up now
 Sign up for general news too

Privacy Statement
 
 
 

Clinical Medicine: Dermatology

Synopsis: An open access, peer reviewed electronic journal that covers diagnosis, management and prevention of skin conditions.


Indexing: 2 major databases.  Pubmed indexing for NIH-funded research.

Processing time: Decision in 2 weeks for 90% of papers.

Visibility: Most popular article read 70+ times.

View factor
for journal
19162


About this journal

ISSN: 1178-6582


Aims and scope:

Clinical Medicine: Dermatology is an international, open access, peer reviewed journal which considers manuscripts on all aspects of the diagnosis, management and prevention of disorders of the skin, in addition to related genetic, pathophysiological and epidemiological topics.

Editorial standards and procedures:

Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers.  Reviewers are required to provide fair, balanced and constructive reports.  

Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair.  Appeals are considered by the Editor in Chief or Associate Editor.

Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.

Indexing:

This journal is indexed by:

  • Google Scholar 
  • OAIster

National Institutes of Health Public Access Policy compliant:

As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.

If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf. 



 
 
 


An Appropriate Response to the Black-Box Warning: Corrective, Barrier Repair Therapy in Atopic Dermatitis

Authors: Peter M. Elias
Publication Date: 09 Feb 2009
Clinical Medicine: Dermatology 2009:2 1-3

Peter M. Elias

Dermatology Service, Veterans Affairs Medical Center, and Department of Dermatology, University of California, San Francisco, CA.

Abstract

Due to years of sophisticated research on T cell function, many dermatologists have viewed atopic dermatitis (AD) largely as an inflammatory disorder of TH1/TH2 imbalance. Hence, therapy has largely consisted of topical immunomodulators and/or steroids. The imposition of “black box” warnings about the potential toxicity associated with prolonged use of the immunosuppressive drugs, tacrolimus 0.1% or 0.3% ointment (Protopic®, Astellas Pharma U.S., Inc., Deerfield, IL) and pimecrolimus 1% cream (Elidel®, Novartis, Basel, Switzerland), as well as legitimate concerns about the adverse side effects of potent topical steroids, has stimulated a search for alternate forms of therapy. Recent genetic studies point to the primary role of a defective barrier to water loss and microbial invasion in the provocation of AD, creating a rationale for ‘barrier repair’ therapy. This approach utilizes topical applications of specific combination of the three (3) epidermal lipids that comprise the epidermal permeability barrier in a ratio (ceramide-dominant) that corrects the biochemical abnormality in AD.1,2 We review here both recent concerns about the topical immunomodulators, as well as the rationale for barrier repair therapy.

Categories: Dermatology


Post comment




No comments yet...Be the first to comment.

Bookmark this article

LINKEDIN FACEBOOK

Add to Mixx! MIXX YAHOO! BUZZ

PERMALINK DIGG


Sign up for free journal updates

How should we address you?
Your email address
 Yes, sign up now




Related journals...